<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03101644</url>
  </required_header>
  <id_info>
    <org_study_id>UCL-LB-02</org_study_id>
    <nct_id>NCT03101644</nct_id>
  </id_info>
  <brief_title>Optimization of Darunavir Therapy and Dosage Recommendations</brief_title>
  <official_title>Optimization of Darunavir Therapy Through Population Pharmacokinetic Modeling, Simulations and Dosage Guidelines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess and characterize the variability observed in the response to darunavir
      therapy, an antiretroviral medication used against the Human Immunodeficiency Virus (HIV).
      More specifically, it aims to quantify variations in the drug's blood concentrations and
      determine the sources of such variability, both genetic and non-genetic. In light of this
      information, current dosage guidelines will then be reviewed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data will be used to create a population pharmacokinetic model. Inter- and intra-individual
      pharmacokinetic variability will be quantified and linked to patient-specific covariates,
      both genetic and non-genetic in nature. Pharmacokinetic-pharmacodynamic relationships will be
      established, linking drug exposure to efficacy (as measured by CD4 cell count and viral load
      reduction) and toxicity (as measured by frequency and degree of adverse events). Simulations
      will be conducted for specific patient profiles and current dosage guidelines reviewed.

      Pharmacokinetic design : combined sparse/intensive sampling

        -  Sparse sampling : One blood sample collected in each individual at a random post-intake
           time (during a routine visit to the hospital), up to three times over the course of the
           study period (months 1-18).

        -  Intensive sampling : Eight blood samples collected over six hours in a subset of twelve
           individuals (during an additional observation period, months 19-22).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 23, 2017</start_date>
  <completion_date type="Actual">June 12, 2019</completion_date>
  <primary_completion_date type="Actual">June 12, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Darunavir clearance</measure>
    <time_frame>Up to 18 months (blood sampling for PK once at each visit, three visits per patient over the study period)</time_frame>
    <description>Assessment of darunavir whole-body clearance and inter-compartmental clearance through population pharmacokinetic methods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Darunavir volume of distribution</measure>
    <time_frame>Up to 18 months (blood sampling for PK once at each visit, three visits per patient over the study period)</time_frame>
    <description>Assessment of darunavir volume of distribution through population pharmacokinetic methods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Darunavir absorption rate</measure>
    <time_frame>Up to 18 months (blood sampling for PK once at each visit, three visits per patient over the study period)</time_frame>
    <description>Assessment of darunavir absorption rate through population pharmacokinetic methods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Darunavir area under the concentration-time curve (AUC)</measure>
    <time_frame>Up to 18 months (blood sampling for PK once at each visit, three visits per patient over the study period)</time_frame>
    <description>Assessment of darunavir area under the concentration-time curve through population pharmacokinetic methods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Darunavir maximum plasma concentration (Cmax)</measure>
    <time_frame>Up to 18 months (blood sampling for PK once at each visit, three visits per patient over the study period)</time_frame>
    <description>Assessment of darunavir maximum plasma concentration through population pharmacokinetic methods</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events/laboratory abnormalities</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Assessment of the frequency of adverse events or laboratory abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in viral load</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Assessment of the change in viral load (HIV copies/ml of blood)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood Cluster of Differentiation 4 (CD4+) T lymphocyte count</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Assessment of the change in blood CD4+ T lymphocyte count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ritonavir/cobicistat AUC</measure>
    <time_frame>Up to 18 months (blood sampling for PK once at each visit, three visits per patient over the study period)</time_frame>
    <description>Assessment of the pharmacokinetic booster (either ritonavir or cobicistat, depending on the subject) AUC through population pharmacokinetic methods</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Human Immunodeficiency Virus I Infection</condition>
  <arm_group>
    <arm_group_label>Darunavir</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients treated with darunavir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <description>The investigated drugs are Prezista (darunavir 600 mg twice-daily or 800 mg once-daily) and Rezolsta (darunavir 800 mg/cobicistat 150 mg once-daily)</description>
    <arm_group_label>Darunavir</arm_group_label>
    <other_name>Prezista</other_name>
    <other_name>Rezolsta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of giving informed consent

          -  HIV-positive

          -  Routinely followed at the Cliniques universitaires Saint-Luc

          -  Treated with darunavir

        Inclusion Criteria (intensive sampling):

        - Perfect adherence to treatment (as assessed by anamnesis and based on available PK data
        for each patient)

        Exclusion Criteria:

        - N/A
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leila Belkhir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires Saint-Luc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 23, 2017</study_first_submitted>
  <study_first_submitted_qc>March 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2017</study_first_posted>
  <last_update_submitted>August 30, 2019</last_update_submitted>
  <last_update_submitted_qc>August 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université Catholique de Louvain</investigator_affiliation>
    <investigator_full_name>Laure Elens</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darunavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

